ACM
MIRM icon

Accent Capital Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Accent Capital Management’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-347
Closed -$6.45K – 328
2026
Q1 		$6.45K Hold
347
– – ﹤0.01% 251
2025
Q4 		$8.13K Hold
347
– – ﹤0.01% 222
2025
Q3 		$8.07K Hold
347
– – ﹤0.01% 244
2025
Q2 		$7.47K Buy
+347
New +$15.4K ﹤0.01% 279

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Accent Capital Management's MIRM Position: Q2 2026 in Review

Accent Capital Management sold out of Mirum Pharmaceuticals (MIRM) in Q2 2026, closing a stake of 347 shares — an estimated $6.45K sold.

Accent Capital Management first reported a position in MIRM in Q2 2025 and held it in 4 quarters. The position peaked at $8.13K in Q4 2025. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Accent Capital Management reported no remaining Mirum Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Accent Capital Management sold 347 Mirum Pharmaceuticals shares in Q2 2026, an estimated $6.45K.
  • Accent Capital Management first reported a position in Mirum Pharmaceuticals in Q2 2025 and held it in 4 quarters.
  • Accent Capital Management's Mirum Pharmaceuticals position peaked at $8.13K in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Accent Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.